CARLSBAD, CA - Invitrogen Corporation announced in a press release that it has signed non-exclusive agreements with New England Biolabs  Inc., QIAGEN GmbH, and Kirkegaard & Perry Laboratories Inc. (KPL), whereby the companies have licensed Invitrogen's patented technology covering the random prime amplification of nucleic acids. Financial terms of the agreements were not disclosed.

The Invitrogen technology covered in these agreements involves methods and kits for substantially amplifying nucleic acids. It is useful in several common laboratory techniques, including random primed labeling reactions, first-strand cDNA synthesis, and whole genome amplification.

"Our random prime amplification technology is an important tool in our premier portfolio of products for genetic analysis," Invitrogen Vice President of Gene Expression Profiling Amy Butler said.

"By making this technology broadly available to other companies through licensing, we can extend the benefit to a greater number of researchers and advance this rapidly growing field of research," he added.

Invitrogen Corporation provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition.

Source: ag-IP-news